<DOC>
	<DOCNO>NCT02968602</DOCNO>
	<brief_summary>Craving cigarette important aspect lead challenge smoke cessation . Persons schizophrenia likely smoke heavy smoker person without schizophrenia , may experience crave differently well . Minocycline antibiotic medication may impact crave . We conduct two-week randomize , double-blind , placebo-controlled , parallel group pilot study investigate effect minocycline vs. placebo crave smoke behavior smoker schizophrenia . Participants take minocycline match placebo two week . Participants assess aspect crave smoke behavior baseline 1 2 week minocycline placebo treatment .</brief_summary>
	<brief_title>Minocycline Tobacco Craving Smokers With Schizophrenia</brief_title>
	<detailed_description>Nicotine dependence high schizophrenia ; nearly three time prevalent general population . In smoker schizophrenia , risk all-cause mortality double cardiovascular mortality risk twelvefold high nonsmoker . Many factor influence smoke person schizophrenia , predictor crave smoking behavior well establish . Craving major contributor smoking behavior , , importantly , predictor relapse risk . Since craving may precede relapse , advantageous screen tool attempt cessation . In addition , focus treatment aim reduce crave may lead good therapeutic target . Minocycline may affect craving , perhaps due inhibition nitric oxide ( NO ) formation , NO act second messenger glutamate dopamine receptor . NO also facilitate effect nicotine reward circuit , blockade NO demonstrate eliminate nicotine abstinence symptom rat . A small study demonstrate minocycline reduces cigarette crave human subject without severe mental illness . The investigator conduct two-week randomize , double-blind , placebo-controlled , parallel group pilot study investigate effect minocycline vs. placebo crave indicator smoke intensity smoker schizophrenia . Participants take minocycline 200 mg daily match placebo two week . Participants complete cigarette cue-elicited craving platform related assessment baseline , 1 2 week minocycline placebo treatment .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Inclusion Criteria DSMIV DSM5 diagnosis schizophrenia schizoaffective disorder Male Female Age : 18 65 year Caucasian NonCaucasian Smoke least 10 cigarette daily Urine cotinine level ≥ 100 ng/ml ( NicAlert® read ≥ 3 ) Agrees wear head mount display ( HMD ) 45 minute Able complete Evaluation Sign Consent ( ESC ) minimum score 80 % Exclusion Criteria History organic brain disease DSMIV diagnosis Alcohol Substance Dependence within last six month ( except nicotine ) DSM5 diagnosis Substance Use Disorder last six month ( except nicotine ) DSMIV diagnosis Alcohol Substance Abuse within last one month ( except nicotine ) DSM5 diagnosis Substance Use Disorder last six month ( except nicotine ) Pregnancy lactation Severe liver dysfunction ( LFT 3X upper limit normal ) Previous know hypersensitivity tetracycline Current treatment tetracycline derivative Treatment oral contraceptive ( unless second form birth control use document ) Treatment cholestyramine colestipol Treatment Urinary alkalinizers ( e.g. , sodium lactate , potassium citrate ) Treatment warfarin Treatment bupropion , varenicline , nicotine replacement product month prior study inclusion Less two month treatment adjunctive medication AND less one month dose : beta blocker , antidepressant , mood stabilizer , antianxiety medication . Medical condition whose pathology treatment would significantly increase risk associate propose protocol . History head injury , seizure , stroke Positive urine toxicology screen substance nontherapeutic use prior craving assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>